Tapentadol is a centrally-acting synthetic analgesic with a dual mechanism of action: mu-opioid receptor (MOR) agonism and norepinephrine reuptake inhibition (NRI). It is classified as a Schedule H1 drug in India, indicating a high potential for abuse and dependence. It is used for the management of moderate to severe acute and chronic pain, including neuropathic pain associated with diabetic peripheral neuropathy. Its unique dual mechanism may offer a favorable side effect profile, particularly regarding gastrointestinal tolerability, compared to classical opioids.
Adult: For acute pain: 50-100 mg every 4-6 hours as needed for pain. The first dose can be 50-100 mg. Maximum daily dose: 600-700 mg. For chronic neuropathic pain associated with DPN: Start at 50 mg twice daily. May be titrated to 100 mg twice daily based on tolerability and pain relief.
Note: Tablet can be taken with or without food. Swallow whole with a glass of water. Do not crush, chew, or break the tablet. Dosing interval: Every 4-6 hours for immediate-release formulations. For missed dose, take as soon as remembered if needed for pain; do not double the dose.
Tapentadol exerts its analgesic effect through a dual mechanism: 1) Agonist activity at the mu-opioid receptor (MOR), which modulates pain perception in the central nervous system. 2) Inhibition of norepinephrine reuptake (NRI), which enhances descending inhibitory pain pathways in the spinal cord. This combination is synergistic and allows for effective analgesia with potentially lower MOR-mediated side effects.
Pregnancy: Category C: Animal studies have shown adverse effects. There are no adequate and well-controlled studies in pregnant women. Use only if the potential benefit justifies the potential risk to the fetus. Prolonged use during pregnancy can result in neonatal opioid withdrawal syndrome (NOWS), which may be life-threatening.
Driving: May impair mental and/or physical abilities required for performing potentially hazardous tasks like driving or operating machinery. Caution patients not to drive or use machinery until they know how the drug affects them.
| Other Opioids (e.g., Morphine, Oxycodone) | Additive CNS and respiratory depression, increased risk of sedation and overdose. | Major |
| Benzodiazepines (e.g., Alprazolam, Diazepam) | Profound sedation, respiratory depression, coma, and death. | Major |
| Alcohol | Additive CNS depression, increased risk of life-threatening respiratory depression. | Major |
| Serotonergic Drugs (e.g., SSRIs, SNRIs, TCAs, Triptans) | Increased risk of serotonin syndrome. | Major |
| MAO Inhibitors (e.g., Phenelzine, Selegiline) | Risk of serotonin syndrome, excitability, and hyperpyrexia. Contraindicated. | Contraindicated |
| CNS Depressants (e.g., Antipsychotics, Sedative Antihistamines) | Increased sedative effects and respiratory depression. | Moderate |
| Mixed Agonist/Antagonist Opioids (e.g., Pentazocine, Nalbuphine) | May reduce analgesic effect and precipitate withdrawal. | Moderate |
| Anticholinergics (e.g., Atropine, Amitriptyline) | Increased risk of urinary retention and severe constipation. | Moderate |